ProfileGDS5678 / 1458619_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 38% 38% 39% 38% 37% 37% 38% 38% 38% 38% 38% 38% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9034438
GSM967853U87-EV human glioblastoma xenograft - Control 22.8647738
GSM967854U87-EV human glioblastoma xenograft - Control 32.8730338
GSM967855U87-EV human glioblastoma xenograft - Control 42.83139
GSM967856U87-EV human glioblastoma xenograft - Control 52.8128238
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9385137
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8932137
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.84838
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8445238
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8602638
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8535738
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8368938
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8630638
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.860138